


PRODUCT INFORMATION



Pamiparib

Item No. 33182

CAS Registry No.: 1446261-44-4
Formal Name: (10aR)-2-fluoro-5,8,9,10,10a,11-hexahydro-10a-methyl-5,6,7a,11-tetraazacyclohepta[def]cyclopenta[a]fluoren-4(7H)-one
Synonym: BGB-290
MF: C₁₆H₁₅FN₄O
FW: 298.3
Purity: ≥98%
UV/Vis.: λ_{max}: 225, 262, 297 nm
Supplied as: A solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Pamiparib is supplied as a solid. A stock solution may be made by dissolving the pamiparib in the solvent of choice, which should be purged with an inert gas. Pamiparib is soluble in organic solvents such as DMSO and dimethyl formamide (DMF). The solubility of pamiparib in DMSO and DMF is approximately 1 and 20 mg/ml, respectively.

Pamiparib is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, pamiparib should first be dissolved in DMF and then diluted with the aqueous buffer of choice. Pamiparib has a solubility of approximately 0.09 mg/ml in a 1:10 solution of DMF:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

Pamiparib is an inhibitor of poly(ADP-ribose) polymerase 1 (PARP1) and PARP2 (IC₅₀s = 1.3 and 0.92 nM, respectively).¹ It is selective for PARP1 and PARP2 over PARP3 (IC₅₀ = 0.068 μM) and other PARP isoforms (IC₅₀s = 2.4->100 μM), as well as over tankyrase 1 (TNKS1) and TNKS2 (IC₅₀s = 0.23 and 0.14 μM, respectively). Pamiparib inhibits PARP activity induced by hydrogen peroxide in HeLa cells with an IC₅₀ value of 0.24 nM. It selectively inhibits proliferation of MDA-MB-436 cells expressing mutant BRCA1 and Capan-1 cells expressing mutant BRCA2 (EC₅₀s = 41 and 960 nM, respectively) over MDA-MB-231 cells expressing wild-type BRCA (EC₅₀ = ~9,000 nM). Pamiparib (1.6-6.3 mg/kg twice per day) induces tumor regression in an MDA-MB-436 mouse xenograft model. It also potentiates increases in survival induced by temozolomide (Item No. 14163) in an H209 mouse xenograft model of small cell lung cancer brain metastasis.

Reference

1. Xiong, Y., Guo, Y., Liu, Y., *et al.* Pamiparib is a potent and selective PARP inhibitor with unique potential for the treatment of brain tumor. *Neoplasia* **22**(9), 431-440 (2020).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 10/31/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM